Phase 3 Neurology Deal Benchmarks

Phase 3 neurology licensing deals carry a median total deal value of $4.1B, with upfront payments ranging from $459M to $1.1B. At this stage, deal structures are shifted toward higher upfront allocations, reflecting reduced regulatory risk and near-term commercial potential. The recommended split allocates 19% to upfront and 81% to milestones.

The neurology landscape at the phase 3 stage is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Development milestones average $492M, regulatory milestones contribute $1.1B, and commercial milestones reach $1.7B. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches.